Zibotentan (DrugBank: Zibotentan)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 51 | Scleroderma | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02047708 (ClinicalTrials.gov) | October 2014 | 22/1/2014 | Zibotentan Better Renal Scleroderma Outcome Study | A Phase II, Single Centre, Randomised, Placebo-controlled, 3-part Trial to Assess the Safety, Tolerability and Efficacy of Zibotentan in Patients With Renal Disease Secondary to Scleroderma | Scleroderma;Scleroderma Renal Crisis;Chronic Kidney Disease | Drug: Zibotentan | University College, London | Medical Research Council | Completed | 18 Years | N/A | All | 27 | Phase 2 | United Kingdom |
| 2 | EUCTR2013-003200-39-GB (EUCTR) | 01/04/2014 | 04/04/2014 | Investigation of Zibotentan for kidney disease in scleroderma | A phase II, single centre, randomised, placebo-controlled, 3-part trial to assess the safety, tolerability and efficacy of Zibotentan in patients with renal disease secondary to scleroderma - Zibotentan better renal scleroderma outcome study (ZEBRA) | Renal complications of systemic sclerosis (scleroderma renal crisis and chronic kidney disease). MedDRA version: 16.1;Level: LLT;Classification code 10064848;Term: Chronic kidney disease;System Organ Class: 100000004857 MedDRA version: 16.1;Level: PT;Classification code 10061087;Term: Connective tissue disorder;System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders MedDRA version: 16.1;Classification code 10018124;Term: Generalized scleroderma;Classification code 10069339;Term: Acute kidney injury;System Organ Class: 100000004857 ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] | University College London | NULL | Not Recruiting | Female: yes Male: yes | 72 | Phase 2 | United Kingdom |